RE:RE:RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyThe oncolytic virus reovirus (pelareorep) has demonstrated that it can convert cold tumors into "hot" tumor by overcoming a hostile (hypoxic) tumor microenvironment (TME) and turning such a hostile TME into one that is more conducive for treatment with immune checkpoint inhibitors, like Roche's atezolizumab (Tecentriq), for example.
Recent work published in October 2024 has concluded that " A combination of checkpoint inhibitors, such as PD-1/PD/L1 antibodies, with hypoxia-targeted therapies ( such as ONCY's pelareorep for example) could disrupt evasion immune response by upregulation of immune checkpoint molecules, such as PD-L1 (as ONCY has demonstrated with pelareorep and tecentriq), that dampens function of CD8+T-cells."
https://link.springer.com/article/10.1007/s10238-024-01501-1
In November 2023 ONCY presented the following, which supports the above upregulation of PD-L1 checkpoint inhibitor and the prevention of the dampening of CD8+ T cells ..... " “Previously published analyses from AWARE-1 patient samples showed that in the first three days after dosing, pelareorep upregulated tumor PD-L1 expression in the tumors, induced the generation and expansion of T cell clones, and promoted the tumor infiltration of CD8+ T cells. It also led to an increase in the CelTIL score in most patients, which is a measure of tumor cellularity and immune infiltration that is associated with favorable clinical outcomes. The new IMC data presented today show an increase in cytotoxic T cells and PD-L1 expression in tumors by three days following treatment and demonstrate pela’s ability to induce an enhanced immune state within tumors. This supports pelareorep’s ability to modify the tumor microenvironment and enhance the responsiveness of cancers to checkpoint inhibitor therapy.”
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-present-further-positive-pelareorep-translational-data-at-sitc/